As chikungunya cases continue to surge globally, healthcare providers must recognize that infection outcomes are not uniform, and genetic factors play a critical role in disease progression. Clinical teams should understand three key points: first, up to 40% of patients will develop persistent joint symptoms extending beyond six months, requiring long-term management strategies. Second, genetic variations in immune response pathways significantly influence who develops chronic complications, suggesting that future diagnostic testing may predict susceptibility. Third, currently no specific targeted treatments exist for chronic chikungunya arthralgia, making early identification and supportive care essential. Research into HLA polymorphisms and cytokine response pathways may eventually enable personalized medicine approaches. Clinicians managing chikungunya patients should maintain vigilance for persistent arthralgia development and counsel patients that genetic predisposition, rather than infection severity, may determine their long-term prognosis. Read the full article on GMJ Newsroom.
Was this article helpful?
